top of page

Cancer Research Methodology for Novel qRT-PCR Assays

To Detect and Quantify Gene Expression and Mutations

The main challenges in developing qRT-PCR assays for cancer screening are identifying suitable biomarkers, designing specific and efficient primers and probes, optimising assay parameters, and validating the assay using human biospecimens. Validate the assay using diverse specimens, such as blood, saliva, or tissue biopsies, to confirm its performance in detecting the target biomarker in the intended patient population.


Here we outline a systematic methodology to develop novel quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) assays for cancer screening. 

Our approach incorporates in silico design, target identification, assay optimisation, and validation for early detection of cancer biomarkers. By leveraging advancements in bioinformatics, machine learning, and laboratory techniques, we outline a streamlined and efficient process for creating highly sensitive and specific qRT-PCR assays for cancer screening.


Background and Significance

Cancer remains a leading cause of mortality worldwide, with early detection being crucial for improving patient outcomes. Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) is a well-established and widely used technique for detecting gene expression changes, with high sensitivity and specificity, making it an ideal tool for cancer screening. However, the development of novel qRT-PCR assays for cancer screening presents several challenges, including the identification of suitable biomarkers and the optimisation of assay parameters.

Advantages of qRT-PCR for Cancer Screening

qRT-PCR offers several advantages over other methods for cancer screening, such as its ability to detect low levels of target transcripts, its quantitative nature, its high specificity, and its relatively low cost. Moreover, qRT-PCR can be easily adapted to high-throughput platforms, allowing for the simultaneous screening of multiple samples.

Challenges in Developing qRT-PCR Assays for Cancer Screening

The main challenges in developing qRT-PCR assays for cancer screening are identifying suitable biomarkers, designing specific and efficient primers and probes, optimising assay parameters, and validating the assay using clinical samples.


Target Identification:

Selection of Cancer Biomarkers

A thorough literature review and database search should be performed to identify potential cancer biomarkers. Several online resources, such as the Human Protein Atlas, NCBI Gene Expression Omnibus (GEO), and The Cancer Genome Atlas (TCGA), can be utilised to identify genes with aberrant expression patterns in cancer tissues compared to normal tissues.

Differential Gene Expression Analysis

Using publicly available datasets or newly generated RNA-seq data can be conducted to identify potential biomarker candidates. Several tools, such as DESeq2, edgeR, and limma, can be employed to perform this analysis, and a combination of fold change and false discovery rate (FDR) cutoffs should be used to determine significantly differentially expressed genes.

Prioritising Target Genes

Prioritise target genes based on their biological relevance, association with cancer progression or metastasis, and potential clinical utility. In addition, consider the expression level, tissue specificity, and potential cross-reactivity with other genes.

In Silico Design of qRT-PCR Assays:

Primer and Probe Design

Utilise bioinformatics tools, such as Primer3, Primer-BLAST, and OligoAnalyzer, to design specific and efficient primers and probes. Ensure that the designed primers and probes meet criteria such as appropriate melting temperatures, amplicon length, and lack of secondary structures.

Melting Temperature and Secondary Structure Prediction

Evaluate the melting temperature (Tm) and secondary structure of the designed primers and probes using nucleic acid structure prediction tools such as UNAFold and mFold. Aim for a Tm within a narrow range to ensure consistent annealing temperatures and minimise primer-dimer formation and secondary structures that may reduce assay efficiency.

Specificity and Efficiency Evaluation

Check the specificity of the designed primers and probes using in silico tools such as Primer-BLAST and BLAST. Optimise the primer and probe sequences to minimise the potential for off-target amplification and ensure high assay efficiency.

Assay Optimisation:

qRT-PCR Reaction Conditions

Optimise the qRT-PCR reaction conditions, including primer and probe concentrations, annealing temperatures, and cycle numbers, to achieve the best possible sensitivity and specificity.

Standard Curve Generation

Generate a standard curve using serial dilutions of template cDNA or synthetic RNA to determine the dynamic range, amplification efficiency, and limit of detection of the assay.

Analytical Sensitivity and Specificity Testing

Assess the analytical sensitivity and specificity of the assay using well-characterised cell lines or clinical samples. Confirm that the assay can detect the target transcripts with high sensitivity and specificity without cross-reactivity to non-target genes.


Clinical Sample Testing

Validate the assay using diverse clinical samples, such as blood, saliva, or tissue biopsies, to confirm its performance in detecting the target biomarker in the intended patient population.

Reproducibility and Robustness Assessment

Evaluate the reproducibility and robustness of the assay by performing inter-assay and intra-assay comparisons and testing different operators, instruments, and reagent lots.

Comparison to Existing Cancer Screening Methods

Compare the performance of the developed qRT-PCR assay to existing cancer screening methods, such as imaging techniques or other molecular diagnostic assays, to determine its relative sensitivity, specificity, and clinical utility.

Integration of Machine Learning and Bioinformatics

Machine Learning for Biomarker Discovery

Leverage machine learning algorithms, such as random forests, support vector machines, and deep learning, to analyse large-scale gene expression data and identify potential biomarkers. Feature selection techniques, such as recursive feature elimination (RFE) and least absolute shrinkage and selection operator (LASSO) regularisation, can reduce the number of candidate genes and select the most informative features.

Bioinformatics Tools for Assay Design

Utilise bioinformatics tools to streamline the process of primer and probe design. These tools can help assess the quality of the designed primers and probes, predict their performance, and identify potential off-target binding sites, thus increasing the efficiency of the assay design process.

Machine Learning for Assay Optimization and Validation

Apply machine learning algorithms to optimise qRT-PCR assay parameters, such as annealing temperatures, primer and probe concentrations, and cycling conditions. Moreover, machine learning can analyse large datasets generated during assay validation, allowing for rapid and accurate assessment of assay performance.

Additional Considerations

Ethical and Regulatory Considerations

When developing qRT-PCR assays for cancer screening, it is crucial to consider ethical and regulatory aspects. The use of clinical samples and patient data must adhere to ethical guidelines and obtain the necessary approvals from Institutional Review Boards (IRBs) or Ethics Committees. Moreover, compliance with regulatory standards, such as the Clinical Laboratory Improvement Amendments (CLIA) and the U.S. Food and Drug Administration (FDA) requirements, should be ensured for the assay's clinical implementation.

Cost and Accessibility

Consider the cost and accessibility of the developed qRT-PCR assay for cancer screening. Efforts should be made to minimise the cost of the assay and ensure that it is affordable for patients and healthcare systems, particularly in low-resource settings. This may involve optimising reagent usage, simplifying the assay workflow, or utilising cost-effective detection systems.

Integration into Clinical Workflow

To maximise the impact of a novel qRT-PCR assay for cancer screening, design with the clinical workflow in mind. Considerations include ease of use, compatibility with existing laboratory equipment and infrastructure, and assay turnaround time. In addition, the assay should be compatible with sample types that can be quickly and noninvasively collected, such as blood or saliva.

Education and Training

To ensure the successful implementation of a novel qRT-PCR assay for cancer screening, it is essential to provide education and training for healthcare professionals and laboratory personnel. This includes the proper execution of the assay, interpretation of the results, and understanding of the assay's limitations.

Long-term Monitoring and Continuous Improvement

Continuously monitor the performance of the developed qRT-PCR assay for cancer screening in real-world settings, collect user feedback, and gather data on assay performance. This information can be used to refine the assay, address any limitations, and improve its overall performance and clinical utility. 


Summary of Methodology

We have outlined a comprehensive methodology for developing novel qRT-PCR assays for cancer screening, including target identification, in silico assay design, optimisation, and validation. By integrating machine learning and bioinformatics tools, our approach aims to streamline the process of qRT-PCR assay development, improve assay performance, and facilitate the discovery of novel cancer biomarkers.

As the field of cancer research continues to evolve, the demand for reliable and efficient cancer screening methods will grow. The methodology presented here can be further refined and adapted to accommodate the development of qRT-PCR assays for various cancer types and stages. Additionally, the integration of advanced machine learning techniques and the continuous improvement of bioinformatics tools will further enhance the process of qRT-PCR assay development, ultimately leading to more effective cancer screening strategies and improved patient outcomes. 

Please click on the links below to inquire about the Compare Biomarket® range of clinical biospecimens and services suitable for your unique human health research needs.

Compare Biomarket Logo



Latest Biosamples, Services and Research Developments

Human Biospecimens for Acute Myeloid Leukaemia Research

Elucidating Molecular and Genetic Characteristics

Board-Certified Pathology Review

Ensuring FFPE Tissue Specimens are Accurately Characterized

Fresh Viable Tissue

Applications Include Biology, Medicine and Pharmacology

bottom of page